CN116349204A - 治疗纤维化的方法 - Google Patents

治疗纤维化的方法 Download PDF

Info

Publication number
CN116349204A
CN116349204A CN202180069900.XA CN202180069900A CN116349204A CN 116349204 A CN116349204 A CN 116349204A CN 202180069900 A CN202180069900 A CN 202180069900A CN 116349204 A CN116349204 A CN 116349204A
Authority
CN
China
Prior art keywords
fibrosis
hydrogen
pulmonary
gli1
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180069900.XA
Other languages
English (en)
Chinese (zh)
Inventor
米格尔·德·洛斯·里奥斯
约翰·胡德
安妮塔·迪弗朗西斯科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endeavour Biopharmaceutical Co
Original Assignee
Endeavour Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endeavour Biopharmaceutical Co filed Critical Endeavour Biopharmaceutical Co
Publication of CN116349204A publication Critical patent/CN116349204A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180069900.XA 2020-10-13 2021-10-13 治疗纤维化的方法 Pending CN116349204A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Publications (1)

Publication Number Publication Date
CN116349204A true CN116349204A (zh) 2023-06-27

Family

ID=81209448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180069900.XA Pending CN116349204A (zh) 2020-10-13 2021-10-13 治疗纤维化的方法

Country Status (8)

Country Link
US (4) US11628167B2 (https=)
EP (1) EP4229828A4 (https=)
JP (1) JP2023546536A (https=)
KR (1) KR20230107568A (https=)
CN (1) CN116349204A (https=)
AU (1) AU2021360767A1 (https=)
CA (1) CA3198661A1 (https=)
WO (1) WO2022081661A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
AU2024230449A1 (en) * 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191736A1 (en) * 2013-05-28 2014-12-04 Redx Pharma Limited Heterocyclic compounds as hedgehog signaling pathway inhibitors
US9000023B2 (en) * 2009-06-19 2015-04-07 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
US20160341726A1 (en) * 2014-02-06 2016-11-24 The Brigham And Women's Hospital, Inc. Uses of gli1 in detecting tissue fibrosis
WO2018082587A1 (zh) * 2016-11-04 2018-05-11 上海瑛派药业有限公司 Hedgehog通路抑制剂在治疗纤维化疾病中的应用
US20200000784A1 (en) * 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases
WO2020018904A1 (en) * 2018-07-19 2020-01-23 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (https=) 1977-06-03 1981-03-07 Pfizer
MY117098A (en) 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
EP1496905B1 (en) 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
ES2377430T3 (es) 2004-09-02 2012-03-27 Genentech, Inc. Inhibidores piridílicos de la señalización de hedgehog
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
CA2681162C (en) 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010017240A2 (en) 2008-08-04 2010-02-11 Amgen Inc. Aurora kinase modulators and methods of use
MX2011004683A (es) 2008-11-03 2011-06-20 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida.
BRPI0921777A2 (pt) 2008-11-17 2016-01-12 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
JP2018535238A (ja) 2015-11-30 2018-11-29 イグナイタ インコーポレイテッド 局所製剤
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
AU2024230449A1 (en) 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9000023B2 (en) * 2009-06-19 2015-04-07 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
WO2014191736A1 (en) * 2013-05-28 2014-12-04 Redx Pharma Limited Heterocyclic compounds as hedgehog signaling pathway inhibitors
US20160341726A1 (en) * 2014-02-06 2016-11-24 The Brigham And Women's Hospital, Inc. Uses of gli1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
WO2018082587A1 (zh) * 2016-11-04 2018-05-11 上海瑛派药业有限公司 Hedgehog通路抑制剂在治疗纤维化疾病中的应用
US20200000784A1 (en) * 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases
WO2020018904A1 (en) * 2018-07-19 2020-01-23 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENGLIN WANG ET AL.: "Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 26, no. 12, 1 May 2018 (2018-05-01), pages 3308 - 3320 *
JOHANNA BENDELL ET AL.: "Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma", CLIN CANCER RES., vol. 24, no. 9, 1 May 2018 (2018-05-01), pages 2082 - 2091 *
ZHENMEI GAO ET AL.: "Effect of mutations on drug resistance of smoothened receptor toward inhibitors probed by molecular modeling", CHEMICAL PHYSICS LETTERS, vol. 741, 17 January 2020 (2020-01-17), pages 1 - 8 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Also Published As

Publication number Publication date
CA3198661A1 (en) 2022-04-21
US12213974B2 (en) 2025-02-04
US20230201195A1 (en) 2023-06-29
JP2023546536A (ja) 2023-11-02
US20240342170A1 (en) 2024-10-17
KR20230107568A (ko) 2023-07-17
AU2021360767A1 (en) 2023-04-27
US12295954B2 (en) 2025-05-13
US11628167B2 (en) 2023-04-18
EP4229828A4 (en) 2024-08-28
EP4229828A1 (en) 2023-08-23
AU2021360767A9 (en) 2024-02-08
WO2022081661A1 (en) 2022-04-21
US20220265650A1 (en) 2022-08-25
US20250235452A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
CN116349204A (zh) 治疗纤维化的方法
US12605377B2 (en) Methods of treating fibrosis
Belcaid et al. Perioperative pain management in morbid obesity
Gonano et al. Comparison of economical aspects of interscalene brachial plexus blockade and general anaesthesia for arthroscopic shoulder surgery
Howton et al. Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma
Kim et al. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas
Steinberg et al. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients
CN120916760A (zh) 治疗纤维化的方法
KR20140022048A (ko) 선택된 환자에서의 피르페니돈 및 항-섬유성 치료제
Sinatra et al. Preoperative rofecoxib oral suspension as an analgesic adjunct after lower abdominal surgery: the effects on effort-dependent pain and pulmonary function
ES2811124T3 (es) Uso de reslizumab para tratar el asma eosinofílica moderada a grave
Shashi et al. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case–control study
Kerstjens et al. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients
Taniguchi et al. Effect of scheduled intravenous acetaminophen on postoperative nausea and vomiting in patients undergoing laparoscopic gynecologic surgery
TWI750129B (zh) 作為血液學毒性生物標記之ｇｄｆ-１５
US9446029B2 (en) Use of NK-1 receptor antagonists in management of visceral pain
US20200368246A1 (en) Combination therapy targeting cancer associated with the hedgehog pathway
Ziqiang et al. Effect of esketamine on the EC50 of remifentanil for blunting cardiovascular responses to endotracheal intubation in female patients under general anesthesia: a sequential allocation dose-finding study
Mieszczański et al. Successful Anesthetic Management for Obese Patients with Interstitial Lung Disease Undergoing Laparoscopic Sleeve Gastrectomy: A Bridge to Improved Lung Transplant Eligibility
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
Samir et al. Dexmedetomidine versus propofol for sedation in stereotactic brain biopsy: a comparative study
TW202535397A (zh) 給藥方案
Nakashima et al. Afatinib-induced bronchiolitis obliterans
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination